Oxford, United Kingdom
Oxford, United Kingdom

Time filter

Source Type

Medd P.,Oxford Radcliffe Hospitals NHS Trust | Monk I.,Oxford Radcliffe Hospitals NHS Trust | Danby R.,University of Oxford | Malladi R.,Oxford Radcliffe Hospitals NHS Trust | And 8 more authors.
International Journal of Hematology | Year: 2011

We investigated the contributions of methotrexate (MTX) and ciclosporin (CsA) prophylaxis to acute/ chronic graft-versus-host disease (a/cGvHD) prevention following reduced-intensity conditioned allogeneic haematopoietic stem cell transplant (HSCT). Ninety-two fludarabine- melphalan sibling allo-SCT received CsA. Nine, 30 and 47 patients received no MTX, 2-3 doses and 4 doses, respectively. Cumulative CsA blood level to day 21 (CsA 21) was calculated. Grades II-IV aGvHD incidence was 37.2%. In multivariate analysis, MTX omission and increasing donor age significantly associated with aGvHD incidence whilst MTX reduction and CsA 21 did not. Median duration of first immunosuppressive therapy (IST) for aGvHD was 68 days; duration of first IST was significantly longer in older patients but was not associated with MTX or CsA 21. Extensive cGvHD incidence was 60.6% at 1 year. Reduction of MTX to 2-3 doses, but not MTX omission or CsA 21, was associated with greater incidence of cGvHD affecting ≥3 organs. Median IST duration was 22 months; neither MTX nor CsA 21 influenced this. IST duration was significantly greater in patients receiving a CD34 dose below median. Neither MTX nor CsA 21 altered survival or relapse outcomes. MTX influences GvHD following T-replete RIC sibling HSCT.

Loading Blood and Transplant Oxford Center collaborators
Loading Blood and Transplant Oxford Center collaborators